SCHEDULE 13G/A

LYELL IMMUNOPHARMA INC

Common Stock par value $0.0001 per share · CUSIP: 55083R104

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• ARCH Venture Fund IX, L.P.

  Shares: 36,412,716.00 · Class: 13.0%

• ARCH Venture Fund IX Overage, L.P.

  Shares: 36,412,716.00 · Class: 13.0%

• ARCH Venture Partners IX, L.P.

  Shares: 36,412,716.00 · Class: 13.0%

• ARCH Venture Partners IX Overage, L.P.

  Shares: 36,412,716.00 · Class: 13.0%

• ARCH Venture Partners IX, LLC

  Shares: 36,412,716.00 · Class: 13.0%

• Keith Crandell

  Shares: 36,412,716.00 · Class: 13.0%

• Clinton Bybee

  Shares: 36,412,716.00 · Class: 13.0%

• Robert Nelsen

  Shares: 36,597,716.00 · Class: 13.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.